Shots:

• The company launches Fyarro (sirolimus protein-bound particles for injectable suspension) for IV use in adult patients with LA unresectable or metastatic malignant PEComa
• Fyarro has been added to the NCCN Guidelines as the preferred mTOR inhibitor to treat malignant PEComa. On Nov 22, 2021, the product has been approved in the US & marks the 1st treatment for the same indication
• The company also launched a patient support program, Aadi Assist to connect patients with co-pay assistance, referrals, educational resources, verification of benefits. The company is also planning to evaluate Fyarro in other tumor types with alterations in mTOR pathway genes

 Ref: Globe Newswire | Image: Aadi Bio